JP7418326B2 - 二重特異性抗体並びにその製造方法及び使用方法 - Google Patents

二重特異性抗体並びにその製造方法及び使用方法 Download PDF

Info

Publication number
JP7418326B2
JP7418326B2 JP2020524012A JP2020524012A JP7418326B2 JP 7418326 B2 JP7418326 B2 JP 7418326B2 JP 2020524012 A JP2020524012 A JP 2020524012A JP 2020524012 A JP2020524012 A JP 2020524012A JP 7418326 B2 JP7418326 B2 JP 7418326B2
Authority
JP
Japan
Prior art keywords
seq
cancer
bispecific antibody
light chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020524012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501575A (ja
JP2021501575A5 (enExample
Inventor
イ ツー，
カトリーナ ブイコワ，
ビル ブレイディ，
ブレア レンショー，
ドン シア，
ゼレン ガオ，
ブライアン コヴァセヴィチ，
ジョナサン ケー． ファレン，
フィル タン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of JP2021501575A publication Critical patent/JP2021501575A/ja
Publication of JP2021501575A5 publication Critical patent/JP2021501575A5/ja
Application granted granted Critical
Publication of JP7418326B2 publication Critical patent/JP7418326B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020524012A 2017-11-02 2018-11-01 二重特異性抗体並びにその製造方法及び使用方法 Active JP7418326B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580845P 2017-11-02 2017-11-02
US62/580,845 2017-11-02
PCT/US2018/058810 WO2019090002A1 (en) 2017-11-02 2018-11-01 Bispecific antibodies and methods of making and using thereof

Publications (3)

Publication Number Publication Date
JP2021501575A JP2021501575A (ja) 2021-01-21
JP2021501575A5 JP2021501575A5 (enExample) 2021-12-09
JP7418326B2 true JP7418326B2 (ja) 2024-01-19

Family

ID=66332369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524012A Active JP7418326B2 (ja) 2017-11-02 2018-11-01 二重特異性抗体並びにその製造方法及び使用方法

Country Status (11)

Country Link
US (1) US20200347137A1 (enExample)
EP (1) EP3703736A4 (enExample)
JP (1) JP7418326B2 (enExample)
KR (2) KR102785809B1 (enExample)
CN (2) CN117343193A (enExample)
AU (1) AU2018358138C1 (enExample)
CA (1) CA3069238A1 (enExample)
IL (1) IL271346A (enExample)
SG (1) SG11202003237QA (enExample)
TW (1) TWI896517B (enExample)
WO (1) WO2019090002A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7383605B2 (ja) * 2017-06-25 2023-11-20 システィミューン， インク． 抗ｐｄ－ｌ１抗体とその作製及び使用方法
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
EP4061849A4 (en) * 2019-11-21 2024-05-29 Brown University BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND CTLA4 WITH IMPROVED CYTOTOXIC EFFECTS ON TUMOR CELLS
EP4069746A4 (en) * 2019-12-04 2023-12-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENT
TW202511295A (zh) * 2023-08-31 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途
CN122161858A (zh) * 2023-09-18 2026-06-05 翰思艾泰生物医药科技(武汉)股份有限公司 靶向ctla4和cd47的抗体及其用途
WO2026061422A1 (en) * 2024-09-18 2026-03-26 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Methods for treating cancer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528925A (ja) 2002-03-29 2005-09-29 ゾーマ テクノロジー リミテッド 多重遺伝子プラスミドおよび組み換えポリペプチドの発現増加法
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
JP2014523401A (ja) 2011-04-20 2014-09-11 アンプリミューン，インコーポレイテッド Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104974253A (zh) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20170073418A1 (en) 2014-12-22 2017-03-16 Systimmune, Inc. Bispecific Tetravalent Antibodies and Methods of Making and Using Thereof
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399618B2 (en) * 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
AU2006230413B8 (en) * 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
EP3683314A1 (en) * 2013-10-07 2020-07-22 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
AU2018366199A1 (en) * 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528925A (ja) 2002-03-29 2005-09-29 ゾーマ テクノロジー リミテッド 多重遺伝子プラスミドおよび組み換えポリペプチドの発現増加法
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
JP2014523401A (ja) 2011-04-20 2014-09-11 アンプリミューン，インコーポレイテッド Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104974253A (zh) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20170073418A1 (en) 2014-12-22 2017-03-16 Systimmune, Inc. Bispecific Tetravalent Antibodies and Methods of Making and Using Thereof
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof

Also Published As

Publication number Publication date
TWI896517B (zh) 2025-09-11
SG11202003237QA (en) 2020-05-28
TW201927819A (zh) 2019-07-16
US20200347137A1 (en) 2020-11-05
JP2021501575A (ja) 2021-01-21
RU2020108444A3 (enExample) 2022-03-17
CN111212658B (zh) 2024-05-03
AU2018358138A1 (en) 2020-04-23
EP3703736A4 (en) 2021-11-03
CA3069238A1 (en) 2019-05-09
NZ763370A (en) 2024-10-25
CN111212658A (zh) 2020-05-29
CN117343193A (zh) 2024-01-05
IL271346A (en) 2020-01-30
KR20250044943A (ko) 2025-04-01
KR20200091382A (ko) 2020-07-30
EP3703736A1 (en) 2020-09-09
KR102785809B1 (ko) 2025-03-26
AU2018358138B2 (en) 2022-06-02
AU2018358138C1 (en) 2022-12-08
WO2019090002A1 (en) 2019-05-09
RU2020108444A (ru) 2021-12-02

Similar Documents

Publication Publication Date Title
CN107428832B (zh) 抗pd-l1抗体
CN109563165B (zh) 抗ctla-4抗体
TWI896517B (zh) 雙專一性抗體及製造與使用其的方法
JP2019517773A (ja) 抗ｌａｇ−３抗体
CN112955469B (zh) 新型拮抗性抗tnfr2抗体分子
CN121248781A (zh) 新颖激动性抗tnfr2抗体分子
CN117285642A (zh) 制导和导航控制蛋白及其制备和使用方法
CN110167966A (zh) 程序性细胞死亡(pd-1)的单结构域抗体
CN110799540A (zh) 多特异性抗体及其制备和使用方法
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
JP2026506623A (ja) 抗ｃｄｈ６抗体及びその使用
US12221480B2 (en) Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof
HK40097105A (en) Bispecific antibodies and methods of making and using thereof
HK40110145A (zh) 新型拮抗性抗tnfr2抗体分子
HK40109442A (en) Novel antagonistic anti tnfr2 antibody molecules
HK40090244A (en) Multispecific antibodies that bind both mait and tumor cells
HK40050308B (en) Novel antagonistic anti tnfr2 antibody molecules
HK40050308A (en) Novel antagonistic anti tnfr2 antibody molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211101

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230922

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240109

R150 Certificate of patent or registration of utility model

Ref document number: 7418326

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350